Literature DB >> 29688090

High and low body mass index may predict severe disease course in children with inflammatory bowel disease.

Anat Yerushalmy-Feler1, Amir Ben-Tov1, Yael Weintraub1, Achiya Amir1, Tut Galai1, Hadar Moran-Lev1, Shlomi Cohen1.   

Abstract

OBJECTIVES: Inflammatory bowel disease (IBD) has been historically associated with underweight and malnutrition. The impact of both underweight and obesity on the clinical course of IBD in adults is controversial. This study described the association between body mass index (BMI) at diagnosis to disease course in children with IBD.
METHODS: We reviewed the medical records of children with IBD from the database of the 'Dana-Dwek' Children's Hospital between 2010 and 2016. Demographic and anthropometric data were collected as were disease characteristics, course and therapy. Patients were categorized in quartiles according to BMI percentiles at diagnosis (Q1-Q4).
RESULTS: Of 100 children who were identified, 62 had Crohn's disease (CD) and 38 had ulcerative colitis (UC). The median age (interquartile range, IQR) at diagnosis was 13.7 (range 11.9-15.2) years. The median (IQR) follow-up was 2.1 (1.2-3.8) years. At diagnosis, 46 children (46%) were in Q1, 20 (20%) in Q2, 19 (19%) in Q3 and 15 (15%) in Q4. Prolonged time to diagnosis was associated with BMI in Q1 and Q4, as well as high disease activity at diagnosis (p < .001). In a multivariate analysis, BMI in the lower and upper quartiles was associated with disease exacerbation (HR 3.212 and 4.651, respectively, p = .016) and anti-tumor necrosis factor (TNF) therapy (HR 4.489 and 3.972, respectively, p = .021).
CONCLUSIONS: BMI in the lower and upper quartiles was associated with more severe disease course in children with IBD. BMI may serve as a simple and highly accessible predictor of pediatric IBD course and prognosis.

Entities:  

Keywords:  BMI; IBD; children; obesity

Mesh:

Substances:

Year:  2018        PMID: 29688090     DOI: 10.1080/00365521.2018.1464595

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  7 in total

1.  Body Mass Index and Disease Activity Are Associated With Moderate to Severe Disability in Crohn's Disease: A Cross-Sectional Study in Shanghai.

Authors:  DongSheng Bian; Yongmei Jiang; Yubei Gu; Zirui He; Qi Chen; Yonghua Tang; Jie Zhong; Yongmei Shi
Journal:  Front Med (Lausanne)       Date:  2021-07-09

2.  Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study.

Authors:  Giuseppe Losurdo; Rosa Federica La Fortezza; Andrea Iannone; Antonella Contaldo; Michele Barone; Enzo Ierardi; Alfredo Di Leo; Mariabeatrice Principi
Journal:  World J Gastroenterol       Date:  2020-12-21       Impact factor: 5.742

Review 3.  Role of Adipose Tissue in Inflammatory Bowel Disease.

Authors:  Eva Karaskova; Maria Velganova-Veghova; Milos Geryk; Hana Foltenova; Veronika Kucerova; David Karasek
Journal:  Int J Mol Sci       Date:  2021-04-19       Impact factor: 5.923

4.  Nomogram to predict primary non-response to infliximab in patients with Crohn's disease: a multicenter study.

Authors:  Xiao-Qi Ye; Jing Cai; Qiao Yu; Xiao-Cang Cao; Yan Chen; Mei-Xin Rao; Bai-Li Chen; Yao He; Zhi-Rong Zeng; Hao Chen; Yi-Mou Lin; Qian Cao; Min-Hu Chen; Sheng-Hong Zhang
Journal:  Gastroenterol Rep (Oxf)       Date:  2020-11-12

Review 5.  Dietary Management in Pediatric Patients with Crohn's Disease.

Authors:  Luca Scarallo; Paolo Lionetti
Journal:  Nutrients       Date:  2021-05-11       Impact factor: 5.717

6.  High body mass index is not associated with increased treatment failure in infliximab treated pediatric patients with inflammatory bowel disease.

Authors:  Isaac Rodin; Justin Chan; Laura Meleady; Clare Hii; Sally Lawrence; Kevan Jacobson
Journal:  JGH Open       Date:  2019-11-23

Review 7.  What was First, Obesity or Inflammatory Bowel Disease? What Does the Gut Microbiota Have to Do with It?

Authors:  Sara Jarmakiewicz-Czaja; Aneta Sokal; Rafał Filip
Journal:  Nutrients       Date:  2020-10-08       Impact factor: 5.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.